Trials / Completed
CompletedNCT00560560
Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments
A Phase II, Single Arm Study Of CP-751,871 In Patients With Refractory Metastatic Adenocarcinoma Of The Colon Or Rectum
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 168 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will test if there is any survival benefit in patients with refractory metastatic colorectal cancer that receive CP-751, 871.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CP-751, 871 | Human IgG2 Monoclonal Antibody. 20mg/kg or 30 mg/kg every 3 weeks for 17 cycles, until progression or unacceptable toxicity develops. |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2010-09-01
- Completion
- 2010-09-01
- First posted
- 2007-11-19
- Last updated
- 2013-05-20
- Results posted
- 2013-05-09
Locations
12 sites across 3 countries: United States, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00560560. Inclusion in this directory is not an endorsement.